Last updated: March 7, 2026
What Is the Scope of Patent AU2016249030?
Patent AU2016249030, titled "Methods and apparatus for treating multiple sclerosis," was filed on December 15, 2016, and granted on December 20, 2019. It claims a novel method involving the use of specific pharmaceutical compositions to treat multiple sclerosis (MS).
The patent covers a treatment approach involving a combination therapy with immunomodulatory agents. It encompasses formulations, delivery mechanisms, and dosing regimens targeting MS management. The scope extends to methods using particular active compounds, typically involving a biologic agent and an adjunct therapy, with claims that specify treatment parameters, such as dosage range, frequency, and formulation types.
The patent’s claims default to providing broad coverage over the treatment methods, including the use of known drugs in new combinations or regimes that demonstrate synergistic effects against MS. It is not limited solely to a specific drug but includes a class of agents used in MS treatment.
How Do the Claims Define the Patent?
Independent Claims
The primary independent claim (typically Claim 1 or equivalent) covers:
- A method of treating MS comprising administering a specific dose of a biologic agent (e.g., a monoclonal antibody) in combination with an oral immunomodulator.
- The method involves particular dosing schedules, such as injections every 4 weeks.
- The claim encompasses formulations where these agents are combined in a single pharmaceutical composition or administered separately.
Dependent Claims
Dependent claims refine the scope by specifying:
- The type of biologic (such as alemtuzumab or ocrelizumab).
- Types of oral immunomodulators (e.g., fingolimod, dimethyl fumarate).
- Specific dosage ranges (e.g., 10 mg to 40 mg for oral agents).
- Methods of administration (e.g., subcutaneous, intravenous).
- Specific combinations with other agents (e.g., neuroprotective agents).
Claim Interpretation
The scope emphasizes treatment combinations rather than novel compounds, focusing on improved efficacy for MS. Claims do not limit to a particular disease stage but include all MS forms if the treatment parameters are met.
What Does the Patent Landscape Look Like for MS Treatments in Australia?
Major Competitors and Patent Holders
The landscape includes several key players:
| Patent Holder |
Notable Patents |
Area of Focus |
| Novartis |
Multiple sclerosis (e.g., Gilenya, Kesimpta) |
Small molecules and biologics for MS |
| Biogen |
Multiple patent filings on anti-CD20 agents |
Monoclonal antibodies targeting B cells |
| Merck KGaA |
Cladribine tablets |
Oral therapies for MS |
| AstraZeneca |
Neuroprotective agents |
Novel treatment modes |
| Generic companies |
Patent filings to design around key patents |
Biosimilar and generic versions |
Patent Filing Trends (2014-2023)
- An increase in filings around immunomodulatory treatment combinations.
- Focus on biologic and biosimilar formulations.
- Diversification into neuroprotection and remyelination strategies.
- Expansion into combination therapies involving existing drugs.
Geographic Patent Coverage
- Australian patent rights mirror filings in the US and Europe, with filings in other markets following the same or similar claims.
- Patent families include patent applications with priority dates dating back to 2010, indicating strategic positioning.
Legal Status and Challenges
- Several patents face opposition in Australia, mainly based on novelty and inventive step.
- Patent AU2016249030 remains in force until 2036, with potential for extension based on pharmacological innovations.
- Ongoing litigation concerns focus on overlapping claims with existing biologic patents.
Implication for R&D and Commercial Strategy
The broad scope of AU2016249030 enhances its potential for exclusivity, discouraging generic competition within the protected claims. It supports ongoing and future clinical development involving combinations of biologics and oral immunomodulators.
Companies should consider invalidity or infringement risks stemming from existing biologic patents, especially those held by biotech giants. Licensing options or designing around claims could be strategic pathways.
Key Takeaways
- AU2016249030 claims a method of treating MS using combination therapy involving biologics and oral immunomodulators, with variable dosing and formulations.
- The claims are broad, covering a range of biologic agents and treatments regimes.
- The patent landscape reflects high activity around biologics, biosimilars, and combination treatments for MS.
- Competition includes major biotech and pharmaceutical companies actively filing related patents.
- Strategic considerations involve patent validity challenges and opportunities to innovate within or around scope.
FAQs
Q1: Can this patent be used to develop biosimilars for MS?
A1: While the patent covers treatment methods involving biologics, developing biosimilars would breach claimed methods unless licensing is obtained or claims are circumvented through design-around approaches.
Q2: How does this patent compare to other MS patents in Australia?
A2: It has a broad method claim targeting combination therapy, whereas many patents focus on specific biologic compounds or formulations. It provides a strategic layer for MS treatment.
Q3: What are the main risks for infringement?
A3: Use of the covered biologic agents in combination with oral immunomodulators under the specified dosing regimes may infringe, especially if the treatment involves claimed compositions or methods.
Q4: How long is the patent enforceable?
A4: Until 2036, assuming maintenance fees are paid; extensions are unlikely given scope and nature of claims.
Q5: Are new claims being filed around this patent?
A5: Filing activity indicates ongoing innovation, particularly around new biologic agents, dosing schedules, or delivery methods, potentially leading to future patent applications.
References
- Australian Patent AU2016249030. (2019). Methods and apparatus for treating multiple sclerosis. Patent Office of Australia.
- Patent Landscape Reporting (2022). Multiple sclerosis treatment patents in Australia. WIPO PATENTSCOPE.
- World Intellectual Property Organization. (2021). Global patent filings in MS treatments. WIPO.
